| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 157, Issue 7 3159-3164, Copyright © 1996 by American Association of Immunologists
ARTICLES |
GS Early, W Zhao and CM Burns
Department of Medicine, Dartmouth Medical School, Lebanon, NH 03768, USA.
Systemic lupus erythematosus is characterized by B cell production of pathogenic autoantibodies dependent upon cooperation from CD4+ Th cells. The interaction between CD40 on B cells and CD40 ligand (CD40L) on Th cells is necessary for normal thymus-dependent Ab production. An anti-murine CD40L mAb blocks binding of CD40L to CD40 and prevents primary and secondary immune responses to thymus-dependent Ags. In this study, New Zealand Black x New Zealand White lupus-prone mice treated with this anti-CD40L Ab from ages 4 to 10 mo had reduced anti-DNA autoantibody production and renal disease and significantly prolonged survival compared with control mice. Pathologic examination verified the absence of significant renal damage or immune deposition in responding mice. Mice that responded to treatment did not develop an Ab response to the administered Ab. Long-term survivors mounted a substantial Ab response to keyhole limpet hemocyanin after completion of anti-CD40L Ab treatment, suggesting that some of the immunosuppressive effects of the Ab may be reversible. These results suggest a human form of this Ab may have therapeutic utility in human systemic lupus erythematosus.
This article has been cited by other articles:
|
|
 |
|
  C B Driver, M Ishimori, and M H Weisman The B cell in systemic lupus erythaematosus: a rational target for more effective therapy Ann Rheum Dis, October 1, 2008; 67(10): 1374 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ramos-Barron, C. Pinera-Haces, C. Gomez-Alamillo, I. Santiuste-Torcida, J.C. Ruiz, L. Buelta-Carrillo, R. Merino, A.L.M. de Francisco, and M. Arias Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment Lupus, October 1, 2007; 16(10): 775 - 781. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Li, K. M. O'Sullivan, L. K. Jones, T. Semple, A. Kumanogoh, H. Kikutani, S. R. Holdsworth, and A. R. Kitching CD100 Enhances Dendritic Cell and CD4+ Cell Activation Leading to Pathogenetic Humoral Responses and Immune Complex Glomerulonephritis. J. Immunol., September 1, 2006; 177(5): 3406 - 3412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Fields, S. A. Nish, B. D. Hondowicz, M. H. Metzgar, G. N. Wharton, A. J. Caton, and J. Erikson The Influence of Effector T Cells and Fas Ligand on Lupus-Associated B Cells J. Immunol., July 1, 2005; 175(1): 104 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamauchi, A. Ishibashi, K. Shikata, N. Tokuhara, K.-i. Seino, S. Kobayashi, and M. Nagai Effect of E6060 [4-{5-[7-Fluoro-4-(trifluoromethyl)benzo[b]furan-2-yl]-1H-2-pyrrolyl}benzoic Acid], a Novel Subtype-Selective Retinoid, on Lupus-Like Nephritis in Female (NZBxNZW)F1 Mice J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 938 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C G Katsiari and G C Tsokos Re-establishment of tolerance: the prospect of developing specific treatment for human lupus Lupus, July 1, 2004; 13(7): 485 - 488. [PDF]
|
|
|
|
|
|
J Yazdany and J Davis The role of CD40 ligand in systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 377 - 380. [Abstract] [PDF]
|
|
|
|
|
|
P I Sidiropoulos and D T Boumpas Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients Lupus, May 1, 2004; 13(5): 391 - 397. [Abstract] [PDF]
|
|
|
|
 |
|
 R. D. Molano, A. Pileggi, T. Berney, R. Poggioli, E. Zahr, R. Oliver, C. Ricordi, D. M. Rothstein, G. P. Basadonna, and L. Inverardi Prolonged Islet Allograft Survival in Diabetic NOD Mice by Targeting CD45RB and CD154 Diabetes, April 1, 2003; 52(4): 957 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C G Katsiari, S-N. Liossis, A M Dimopoulos, D V Charalambopoulos, M Mavrikakis, and P P Sfikakis CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition Lupus, June 1, 2002; 11(6): 370 - 378. [Abstract] [PDF]
|
|
|
|
|
|
S. Nierkens, P. van Helden, M. Bol, R. Bleumink, P. van Kooten, S. Ramdien-Murli, L. Boon, and R. Pieters Selective Requirement for CD40-CD154 in Drug-Induced Type 1 Versus Type 2 Responses to Trinitrophenyl-Ovalbumin J. Immunol., April 15, 2002; 168(8): 3747 - 3754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Lobo, P. R. Scholl, and R. L. Fuleihan CD40 Ligand-Deficient T Cells from X-Linked Hyper-IgM Syndrome Carriers Have Intrinsic Priming Capability J. Immunol., February 1, 2002; 168(3): 1473 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Higuchi, Y. Aiba, T. Nomura, J. Matsuda, K. Mochida, M. Suzuki, H. Kikutani, T. Honjo, K. Nishioka, and T. Tsubata Cutting Edge: Ectopic Expression of CD40 Ligand on B Cells Induces Lupus-Like Autoimmune Disease J. Immunol., January 1, 2002; 168(1): 9 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Wellmann, M. Letz, A. Schneider, K. Amann, and T. H. Winkler An Ig {micro}-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB x NZW)F1 mice Int. Immunol., December 1, 2001; 13(12): 1461 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. Luzina, S. P. Atamas, C. E. Storrer, L. C. daSilva, G. Kelsoe, J. C. Papadimitriou, and B. S. Handwerger Spontaneous formation of germinal centers in autoimmune mice J. Leukoc. Biol., October 1, 2001; 70(4): 578 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, D. S. Smith, A. Guth, and L. J. Wysocki A Receptor Presentation Hypothesis for T Cell Help That Recruits Autoreactive B Cells J. Immunol., February 1, 2001; 166(3): 1562 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M L Huggins, I Todd, and R J Powell CD40 Ligand--an important target for immunotherapy? Lupus, January 1, 2001; 10(1): 1 - 3. [PDF]
|
|
|
|
|
|
S L Kalled, A H Cutler, and J L Ferrant Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis Lupus, January 1, 2001; 10(1): 9 - 22. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Rothstein, M. F. A. Livak, K. Kishimoto, C. Ariyan, H.-Y. Qian, S. Fecteau, M. Sho, S. Deng, X. X. Zheng, M. H. Sayegh, et al. Targeting Signal 1 Through CD45RB Synergizes with CD40 Ligand Blockade and Promotes Long Term Engraftment and Tolerance in Stringent Transplant Models J. Immunol., January 1, 2001; 166(1): 322 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lettesjo, G. P. Burd, and R. A. Mageed CD4+ T Lymphocytes with Constitutive CD40 Ligand in Preautoimmune (NZB NZW)F1 Lupus-Prone Mice: Phenotype and Possible Role in Autoreactivity J. Immunol., October 1, 2000; 165(7): 4095 - 4104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Namba, K. Ogasawara, N. Kitaichi, T. Morohashi, Y. Sasamoto, S. Kotake, H. Matsuda, K. Iwabuchi, C. Iwabuchi, S. Ohno, et al. Amelioration of Experimental Autoimmune Uveoretinitis by Pretreatment with a Pathogenic Peptide in Liposome and Anti-CD40 Ligand Monoclonal Antibody J. Immunol., September 15, 2000; 165(6): 2962 - 2969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. ATEN, A. ROOS, N. CLAESSEN, E. J. M. SCHILDER-TOL, I. J. M. TEN BERGE, and J. J. WEENING Strong and Selective Glomerular Localization of CD134 Ligand and TNF Receptor-1 in Proliferative Lupus Nephritis J. Am. Soc. Nephrol., August 1, 2000; 11(8): 1426 - 1438. [Abstract] [Full Text]
|
|
|
|
|
|
B. Berner, G. Wolf, K. M Hummel, G. A Müller, and M. A Reuss-Borst Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis Ann Rheum Dis, March 1, 2000; 59(3): 190 - 195. [Abstract] [Full Text]
|
|
|
|
|
|
H Amano, S Morimoto, H Kaneko, Y Tokano, Y Takasaki, and H Hashimoto Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers Lupus, January 1, 2000; 9(1): 26 - 32. [Abstract] [PDF]
|
|
|
|
 |
|
 D. M. Harlan and A. D. Kirk The Future of Organ and Tissue Transplantation: Can T-Cell Costimulatory Pathway Modifiers Revolutionize the Prevention of Graft Rejection? JAMA, September 15, 1999; 282(11): 1076 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Kenyon, M. Chatzipetrou, M. Masetti, A. Ranuncoli, M. Oliveira, J. L. Wagner, A. D. Kirk, D. M. Harlan, L. C. Burkly, and C. Ricordi Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154 PNAS, July 6, 1999; 96(14): 8132 - 8137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nakamura, A. Kawakami, S. Yamasaki, Y. Kawabe, T. Nakamura, and K. Eguchi Expression of mitogen activated protein kinases in labial salivary glands of patients with Sjogren's syndrome Ann Rheum Dis, June 1, 1999; 58(6): 382 - 385. [Abstract] [Full Text]
|
|
|
|
|
|
M Harigai, M Hara, C Fukasawa, S Nakazawa, Y Kawaguchi, N Kamatani, and S Kashiwazaki Responsiveness of peripheral blood B cells to recombinant CD40 ligand in patients with systemic lupus erythematosus Lupus, March 1, 1999; 8(3): 227 - 233. [Abstract] [PDF]
|
|
|
|
 |
|
 A. A. ROSSINI, D. L. GREINER, and J. P. MORDES Induction of Immunologic Tolerance for Transplantation Physiol Rev, January 1, 1999; 79(1): 99 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Conde, S. Weller, S. Gilfillan, L. Marcellin, T. Martin, and J.-L. Pasquali Terminal Deoxynucleotidyl Transferase Deficiency Reduces the Incidence of Autoimmune Nephritis in (New Zealand Black New Zealand White)F1 Mice J. Immunol., December 15, 1998; 161(12): 7023 - 7030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S K Datta Production of pathogenic antibodies: Cognate interactions between autoimmune T and B cells Lupus, November 1, 1998; 7(9): 591 - 596. [Abstract] [PDF]
|
|
|
|
|
|
T Kuroiwa and E G Lee Cellular interactions in the pathogenesis of lupus nephritis: The role of T cells and macrophages in the amplification of the inflammatory process in the kidney Lupus, November 1, 1998; 7(9): 597 - 603. [Abstract] [PDF]
|
|
|
|
|
|
G G Illei and J H Klippel Novel approaches in the treatment of lupus nephritis Lupus, November 1, 1998; 7(9): 644 - 648. [Abstract] [PDF]
|
|
|
|
|
|
J. Q. Russell, T. Mooney, P. L. Cohen, B. MacPherson, R. J. Noelle, and R. C. Budd Anti-CD40L Accelerates Renal Disease and Adenopathy in MRL-lpr Mice in Parallel with Decreased Thymocyte Apoptosis J. Immunol., July 15, 1998; 161(2): 729 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Hahn Antibodies to DNA N. Engl. J. Med., May 7, 1998; 338(19): 1359 - 1368. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Kalled, A. H. Cutler, S. K. Datta, and D. W. Thomas Anti-CD40 Ligand Antibody Treatment of SNF1 Mice with Established Nephritis: Preservation of Kidney Function J. Immunol., March 1, 1998; 160(5): 2158 - 2165. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
